ADARx Pharmaceuticals, Inc.

ADRX Nasdaq SEC CIK 1802369
Follow ADARx Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $2.2M +42.6% vs same quarter last year
Net income −$28.1M −57.2% vs same quarter last year
EPS, diluted −$1.74 +5.9% vs same quarter last year
Operating income −$32.2M −39.9% vs same quarter last year
Revenue by quarter
$1.6M
$2.2M
Q3 25 Q3 26

Source: SEC XBRL filings · latest filing